Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS)’s share price traded down 13.5% during mid-day trading on Monday . The stock traded as low as $1.32 and last traded at $1.35. 1,689,247 shares were traded during trading, an increase of 86% from the average session volume of 906,220 shares. The stock had previously closed at $1.56.
Several equities analysts have issued reports on the company. HC Wainwright reiterated a “hold” rating and set a $0.50 target price on shares of Sunesis Pharmaceuticals in a research report on Tuesday, March 12th. Oppenheimer set a $6.00 target price on Sunesis Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, March 8th. Zacks Investment Research cut Sunesis Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, February 9th. Finally, ValuEngine upgraded Sunesis Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, January 2nd. Four analysts have rated the stock with a hold rating and one has given a buy rating to the company. Sunesis Pharmaceuticals currently has a consensus rating of “Hold” and a consensus price target of $2.33.
The firm has a market capitalization of $87.85 million, a price-to-earnings ratio of -1.66 and a beta of 2.66.
Sunesis Pharmaceuticals (NASDAQ:SNSS) last released its quarterly earnings results on Thursday, March 7th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.06. As a group, analysts forecast that Sunesis Pharmaceuticals, Inc. will post -0.66 earnings per share for the current year.
An institutional investor recently bought a new position in Sunesis Pharmaceuticals stock. Aisling Capital Management LP purchased a new position in Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 2,600,000 shares of the biopharmaceutical company’s stock, valued at approximately $1,092,000. Sunesis Pharmaceuticals accounts for about 1.2% of Aisling Capital Management LP’s portfolio, making the stock its 12th largest holding. Aisling Capital Management LP owned approximately 6.95% of Sunesis Pharmaceuticals as of its most recent SEC filing. Hedge funds and other institutional investors own 22.83% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Sunesis Pharmaceuticals (SNSS) Trading Down 13.5%” was first posted by Modern Readers and is owned by of Modern Readers. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. and international trademark and copyright law. The legal version of this piece of content can be viewed at https://www.modernreaders.com/news/2019/04/17/sunesis-pharmaceuticals-snss-trading-down-13-5.html.
Sunesis Pharmaceuticals Company Profile (NASDAQ:SNSS)
Sunesis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers. Its lead program is vecabrutinib, a non-covalently binding inhibitor of Bruton's tyrosine kinase (BTK), which is in Phase 1b/2 clinical trial in B-cell malignancies.
Featured Story: The Structure of a Futures Contract
Receive News & Ratings for Sunesis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunesis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.